

February 11, 2023

To  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G –Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai-400051

Scrip Name: NCD-KPCP29; KPCP33; KPCP24

**Sub: Intimation of newspaper publication of financial results for the quarter and nine months ended December 31, 2022**

Dear Sir/Madam

Pursuant to outcome of Board meeting reported under Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') vide our letter dated February 10, 2023 and pursuant to Regulation 52 (8) the Un-audited financial results for the quarter and nine (9) months ended December 31, 2022 was published on February 11, 2023 in English national daily newspaper i.e. Financial Express.

Please find attached the copy of said publication.

We request you to take the above compliance on record.

Thanking you,  
Yours faithfully,  
For **Kanchanjunga Power Company Private Limited**

Jyoti Chawla  
Company Secretary  
Membership No.: A44668



**Kanchanjunga Power Company Private Limited**

CIN No.: U74899DL1991PTC046387 | GSTIN: 02AABCK9368H1ZG

Corporate Office: B-37, 3rd Floor, Sector - 1, Noida- 201301, Gautam Budh Nagar, (U.P.), India, Board: +91-120 4621300 | Fax: +91-120 4621333

Registered Office: A-26/5, First Floor, Street No. 8, West Vinod Nagar, Delhi-110092

Site: KPCPL Power House, Patnikuhal Shila, Halan II Road, Tehsil Manali, District Kullu - 175129, Himachal Pradesh

**GNRC LTD.**  
 Regd. Office: GNRC Complex, Plot No. 10, Sector 1, Noida - 201301  
 (CIN: U74999DL1991PTC043637) Website: www.gnrc.co.in  
 E-mail: info@gnrc.co.in, gnrc@gnrc.co.in

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2022**  
 (REGULATION 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015)

Sl. No.	Particulars	Quarter ended			Year ended		
		December 31, 2022 (Unaudited)	September 30, 2022 (Unaudited)	December 31, 2021 (Unaudited)	December 31, 2022 (Unaudited)	September 30, 2022 (Unaudited)	December 31, 2021 (Unaudited)
1	Total Income from Operations	6,69,00,000	6,78,00,000	6,78,00,000	29,00,00,000	29,00,00,000	29,00,00,000
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	26,48,000	(1,95,27,000)	(1,95,27,000)	(1,95,27,000)	(1,95,27,000)	(1,95,27,000)
3	Net Profit/(Loss) for the period (after Exceptional and/or Extraordinary Items)	26,48,000	(1,95,27,000)	(1,95,27,000)	(1,95,27,000)	(1,95,27,000)	(1,95,27,000)
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	16,62,750	(12,00,750)	(12,00,750)	(12,00,750)	(12,00,750)	(12,00,750)
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	(53,18,000)	(1,85,30,000)	(1,85,30,000)	(2,57,54,000)	(2,57,54,000)	(2,57,54,000)
6	Paid up Equity Share Capital	1,00,00,000	1,00,00,000	1,00,00,000	1,00,00,000	1,00,00,000	1,00,00,000
7	Reserves (excluding Revaluation Reserve)	(53,78,750)	(1,85,30,000)	(1,85,30,000)	(53,78,750)	(53,78,750)	(53,78,750)
8	Securities Premium Account	1,14,21,000	1,14,21,000	1,14,21,000	1,14,21,000	1,14,21,000	1,14,21,000
9	Net Worth (Basis Section 2(57) of the Companies Act, 2013)	1,70,00,000	1,57,61,000	1,57,61,000	1,57,61,000	1,57,61,000	1,57,61,000
10	Paid up Debt Capital/ Outstanding Debt	3,52,00,000	3,52,00,000	3,52,00,000	3,52,00,000	3,52,00,000	3,52,00,000
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-
12	Debt Equity Ratio	2.07	2.23	2.23	2.23	2.23	2.23
13	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)	0.17	(1.95)	(1.95)	(1.95)	(1.95)	(1.95)
14	Capital Redemption Reserve	-	-	-	-	-	-
15	Debt Service Coverage Ratio	1.08	0.53	0.53	0.53	0.53	0.53
16	Debt Service Coverage Ratio	2.22	1.53	1.53	1.53	1.53	1.53

**Notes:**  
 1. The above is an extract of the detailed format of quarterly standalone unaudited financial results filed with the Stock Exchanges (BSE) under regulation 33 of the Listing Regulations. The full format of the unaudited financial results are available on the website of the Stock Exchange (BSE) www.bseindia.com and the first info (FI) www.firstinfo.com in accordance with the requirements.  
 2. For the items referred in Regulation 33 (4) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the period disclosures are available on the website of the Stock Exchange (BSE) www.bseindia.com.

**For GNRC Ltd.:**  
 Dr. Harish Chandra Bora  
 Chairman and Managing Director  
 DIN: 00658588 Date: 11 February 2023 Place: Noida-14

**GOKALDAS EXPORTS LIMITED**  
 Corporate Identification Number (CIN): L18101KA2004PLC033475  
 Regd. Office: No. 25, 2nd Cross, 3rd Main, Industrial Suburb, Yeshwanthpur, Bangalore-560022.  
 Tel: +91 80 68951000 Fax: +91 80 68951001 E-mail: info@gokaldasexports.com Website: www.gokaldasexports.com

**Statement of unaudited Standalone and Consolidated Ind AS financial results for the quarter and nine months ended December 31, 2022**  
 (Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended		Nine Months Ended		Year Ended		Quarter Ended		Nine Months Ended		Year Ended	
		Dec 31, 2022	Sep 30, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021	Mar 31, 2022	Dec 31, 2022	Sep 30, 2022	Dec 31, 2021	Dec 31, 2022	Dec 31, 2021	Mar 31, 2022
1	Total Income	52,932.57	57,717.09	52,372.00	1,71,964.35	1,21,222.21	1,80,003.49	52,809.53	57,631.95	52,406.41	1,71,710.75	1,21,304.87	1,80,100.34
2	Net profit/(Loss) before tax and exceptional items	4,941.92	4,999.74	3,843.42	15,092.22	6,445.10	11,672.97	4,775.19	4,900.82	3,859.49	14,757.38	6,465.42	11,703.13
3	Net Profit/(Loss) before tax and after exceptional items	4,941.92	5,604.77	3,843.42	15,697.25	6,445.10	11,672.97	4,775.19	5,505.85	3,859.49	15,362.41	6,465.42	11,703.13
4	Net Profit/(Loss) after tax and exceptional items	4,224.82	4,678.95	2,995.14	12,912.22	5,596.82	11,672.97	4,058.09	4,580.03	3,011.21	12,577.38	5,617.14	11,708.13
5	Total Comprehensive Income for the period / year	4,671.23	1,922.03	4,389.38	7,423.91	7,080.86	12,381.87	4,563.55	1,823.86	4,406.20	7,149.62	7,103.43	12,416.61
6	Paid up equity share capital (face value Rs 5 each, fully paid up)	3,028.90	3,028.90	2,948.37	3,028.90	2,948.37	2,948.85	3,028.90	2,948.37	3,028.90	2,948.37	2,948.85	2,948.85
7	Other equity as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	68,014.11	-	-	-	-	-	67,868.70
8	Earnings Per Share (EPS) Basic	6.97	7.73	5.17	21.36	11.65	23.01	6.70	7.56	5.20	20.81	11.69	23.08
8	Diluted	6.63	7.34	5.01	20.32	11.17	22.07	6.37	7.19	5.04	19.79	11.21	22.14

**Notes:**  
 The above is an extract of the detailed format of Quarterly / Half yearly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The full format of the financial results are available on the stock exchange websites www.bseindia.com and www.nseindia.com and on the company's website (www.gokaldasexports.com)

**For Gokaldas Exports Ltd.:**  
 S. Sivaramkrishnan Ganapathi  
 Vice Chairman and Managing Director  
 DIN : 07954560

Place: Bengaluru  
 Date: February 10, 2023

**KANCHANJUNGA**  
**KANCHANJUNGA POWER COMPANY PRIVATE LIMITED**  
 (CIN: U74999DL1991PTC043637)  
 Registered Office: A-26/5, First Floor, Street No-8, West Vinod Nagar, Delhi-110092  
 Corporate Office: B-37, Sector 1, Noida, Gautam Budh Nagar - 201301  
 Phone No. : 0120 4521330; Email Id : pgs.secre@kanchanjunga.com; Website: http://indiahydro.in

**EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022**  
 (Rs. in Lakhs)

Sl. No.	Particulars	Quarter ended			Year ended		
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	September 30, 2022	December 31, 2021
1	Total Income from Operations	4,158.48	3,918.43	2,404.54	3,543.71	3,543.71	3,543.71
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	1,392.48	(500.75)	1,535.67	(844.84)	(844.84)	(844.84)
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	1,922.85	(500.75)	2,222.60	(844.84)	(844.84)	(844.84)
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	1,950.35	(418.45)	2,198.49	(837.04)	(837.04)	(837.04)
5	Paid up Equity Share Capital	2014.20	2014.20	2014.20	2014.20	2014.20	2014.20
6	Reserves (excluding Revaluation Reserve)	(5304.69)	(5304.69)	(4886.24)	(7255.04)	(7255.04)	(7255.04)
7	Securities Premium Account	-	-	-	-	-	-
8	Net Worth	1,469.31	1,469.31	1,827.76	(541.94)	(541.94)	(541.94)
9	Paid up Debt Capital/ Outstanding Debt	10,700.00	10,700.00	10,966.72	11,500.00	11,500.00	11,500.00
10	Outstanding Redeemable Preference Shares	4,699.80	4,699.80	4,699.80	4,699.80	4,699.80	4,699.80
11	Debt Equity Ratio	7.6	7.8	6.0	(21.26)	(21.26)	(21.26)
12	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -	-	-	-	-	-	-
13	a. Basic	7.05	(2.08)	7.50	(3.16)	(3.16)	(3.16)
13	b. Diluted	7.05	(2.08)	7.50	(3.16)	(3.16)	(3.16)
13	Capital Redemption Reserve	-	-	-	-	-	-
14	Debt Service Coverage Ratio	1.98	0.11	3.63	1.45	1.45	1.45
15	Debt Service Coverage Ratio	4.10	0.23	8.57	1.58	1.58	1.58

**Notes:**  
 a. Exceptional and/or Extraordinary Items adjusted in the Statement of Profit and Loss in accordance with AS Rules.  
 b. In terms of Regulation 52 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the aforesaid Statement of Un-audited financial results for the quarter and nine months ended 31 December 2022 of the Company has been approved by the Board of Directors at their meeting held on 10 Feb 2023. The aforesaid financial results for the quarter and nine months ended 31 December 2022 have been subject to limited review by the statutory auditors of the Company.  
 c. The Un-audited financial results have been prepared in accordance with recognition and measurement principles laid down in the applicable Accounting Standards as prescribed under section 133 of the Companies Act, 2013 as amended upto date read with relevant rules made thereunder and in terms of the regulation 52 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended.  
 d. Pertinent disclosures w.r.t. the additional information on the financial results referred to in Regulation 52(4) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, have been made to the National Stock Exchange (NSE) and can be accessed on its website 'www.nseindia.com'.  
 e. The above is an extract of the detailed format of un-audited quarterly financial results filed with NSE under regulation 52 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The detailed financial results are available on the website of the NSE where the NCDs of the Company are listed.

For and on behalf of Board of Directors of Kanchanjunga Power Company Private Limited  
 Pramo Kumar Anora  
 Whole Time Director  
 DIN: 01898696

Place: Noida  
 Date: February 10, 2023

**MEDICAMEN BIOTECH LTD.**  
 Regd. Office: 308, Okhla Vihar Tower 43, Netaji Place, New Delhi-110019  
 (CIN: U74999DL1993PLC05554) E-mail: cs@medicamen.com, www.medicamen.com

**Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Nine months ended on 31.12.2022**  
 (In Lakhs)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended		Nine months ended		Year Ended		Quarter Ended		Nine months ended		Year Ended	
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022	31.12.2022	30.09.2022	31.12.2021	31.12.2021	31.03.2022	
1	Total income from operations (net)	3474.42	3405.69	3346.84	10285.14	9407.39	11716.53	3621.05	3405.69	3346.84	10431.77	9407.39	11716.53
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary Items)	421.18	414.90	507.61	1268.58	1487.51	1810.35	422.26	414.19	507.61	1268.95	1487.51	1809.42
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary Items)	421.18	414.90	507.61	1268.58	1487.51	1810.35	422.26	414.19	507.61	1268.95	1487.51	1809.42
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary Items)	375.94	361.11	377.85	1095.61	1215.17	1490.64	377.02	360.40	377.85	1095.98	1215.17	1489.71
5	Total comprehensive income for the period (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax))	375.94	361.11	377.85	1095.61	1215.17	1490.64	377.02	360.40	377.85	1095.98	1215.17	1489.71
6	Equity Share Capital	1265.11	1265.11	1221.66	1265.11	1221.66	1221.66	1265.11	1265.11	1221.66	1265.11	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	-	-	-	-	-	-	-	-	-	-
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -	2.97	2.85	3.09	8.66	9.95	12.20	2.98	2.85	3.09	8.66	9.95	12.19
8	Basic	2.97	2.85	3.09	8.66	9.95	12.20	2.98	2.85	3.09	8.66	9.95	12.19
8	Diluted	2.97	2.85	3.09	8.66	9.95	12.20	2.98	2.85	3.09	8.66	9.95	12.19

**Notes:**  
 1. The Un-audited financial results for the quarter and nine months ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10.02.2023.  
 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.  
 3. The results are not comparable on quarterly or yearly basis as company is regularly incurring marketing expenses. The company has also recruited and placed senior human resources for the purpose of creating its own marketing network in India and throughout Africa. The company shall start reaping its benefits from next financial year.  
 4. The company operates only in one business segment viz. Pharmaceutical formulations, hence segment reporting is not applicable.  
 5. The Earnings Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earnings per Share".  
 6. Limited review report has been carried out by the Statutory Auditors for the above period.  
 7. The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

**For Medicamen Biotech Limited:**  
 Rahul Bishnoi  
 Chairman

Place: New Delhi  
 Date: 10.02.2023

**RAJPUTANA INVESTMENT & FINANCE LIMITED**  
 (CIN: L69299WB1941PLC019721)  
 Regd. Off.: Rajputana, No. 11110, BPO Complex, NH Bypass, Kondikara, Thrissur, Kerala, 680306, India  
 (CIN: LS0100KL1941PLC078267)  
 Email Id: rajputanainvestment@gmail.com, Website: www.rajputanainvestment.com

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022**  
 (Rs. In Lakhs, except per equity share data)

Particulars	Quarter Ended		Nine Months Ended		Year Ended	
	12/31/22	9/30/22	12/31/21	12/31/22	12/31/21	3/31/22
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Revenue from operations	-	-	-	-	-	-
a) Net Sales/Income from Operations	28.01	23.35	-	57.84	-	28.75
b) Other Operating Income	7.56	7.56	7.90	22.60	21.21	28.75
<b>Total revenue from operations (A)</b>	<b>35.57</b>	<b>30.91</b>	<b>7.90</b>	<b>80.44</b>	<b>21.21</b>	<b>28.75</b>
B. Other income	0.09	0.09	-	0.18	-	-
<b>Total Income (A+B)</b>	<b>35.66</b>	<b>31.00</b>	<b>7.90</b>	<b>80.62</b>	<b>21.21</b>	<b>28.75</b>
C. Expenses	-	-	-	-	-	-
(a) Cost of Material Consumed	-	-	-	-	-	-
(b) Purchases of Stock-in-trade	83.05	-	-	83.05	-	-
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(83.05)	-	-	(83.05)	-	-
(d) Employees Benefit Expenses	12.49	13.06	0.30	35.89	2.65	6.42
(e) Finance Cost	0.20	0.17	0.03	0.47	0.10	0.23
(f) Depreciation & Amortization Expenses	0.07	0.31	-	4.19	3.75	3.75
(g) Selling Fees / Depository Fees	17.94	17.78	3.70	43.38	10.63	20.20
(h) Other Expenses	29.82	31.32	4.03	83.93	17.03	26.85
<b>Total expenses (C)</b>	<b>58.4</b>	<b>(0.32)</b>	<b>3.67</b>	<b>(3.31)</b>	<b>4.18</b>	<b>1.91</b>
D. Profit/(Loss) before tax (A+B-C)	5.84	(0.32)	3.67	(3.31)	4.18	1.91
E. Exceptional Items	-	-	-	-	-	-
F. Tax expense:	-	-	-	-	-	-
(i) Current tax	-	-	0.97	(0.17)	1.05	0.61
(ii) Deferred tax	(0.14)	(0.02)	2.90	(3.14)	3.13	1.41
G. Profit/(Loss) for the period (D+E)	5.86	(0.30)	2.90	(3.14)	3.13	1.41
H. Other comprehensive income	-	-	-	-	-	-
(i) Items that will not be reclassified to profit or loss	-	-				